Estrella Opens Fifth STARLIGHT-1 Site in Salt Lake City
Intermountain Health LDS Hospital has joined Estrella Immunopharma’s Phase I/II study of EB103. Screening and enrollment are expected to begin once site initiation activities are complete.
Estrella Immunopharma 1 article
Cellular medicines are central to Estrella Immunopharma, an allogeneic T-cell therapy company using ARTEMIS receptor engineering for hematologic and autoimmune targets. Its platform is defined by allogeneic T-cell therapy and ARTEMIS T-cell receptor platform, while DLBCL cellular immunotherapy clarifies the relevant cell source, engineering strategy or disease application. The company is further characterized by EB104 CD19 CD22 dual-target T cells, a durable recognition signal for Estrella Immunopharma.